This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by File, T. M. Articles by Berkowitz, E. Search for Related Content PubMed PubMed Citation Articles by File, T. M., Jr. Articles by Berkowitz, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2004, p. 3323-3331, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3323-3331.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adults

T. M. File Jr.,^1* H. Lode,² H. Kurz,³ R. Kozak,⁴ H. Xie,⁴ E. Berkowitz,⁴ and the 600 Study Group

Summa Health System, Akron, Ohio,¹ Hospital Zehlendorf, Berlin, Germany,² GlaxoSmithKline, Harlow, England,³ GlaxoSmithKline, Collegeville, Pennsylvania⁴

Received 5 July 2003/ Returned for modification 1 December 2003/ Accepted 26 April 2004

This randomized, double-blind, noninferiority trial was designed to demonstrate that pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 mg) was at least as effective clinically as amoxicillin-clavulanate 875/125 mg, both given twice daily for 7 days, in the treatment of community-acquired pneumonia in adults. In total, 633 clinically and radiologically confirmed community-acquired pneumonia patients (intent-to-treat population) were randomized to receive either oral amoxicillin-clavulanate 2,000/125 mg (n = 322) or oral amoxicillin-clavulanate 875/125 mg (n = 311). At screening, 160 of 633 (25.3%) patients had at least one typical pathogen isolated from expectorated or invasive sputum samples or blood culture (bacteriology intent-to-treat population). Streptococcus pneumoniae (58 of 160, 36.3%), methicillin-susceptible Staphylococcus aureus (34 of 160, 21.3%), and Haemophilus influenzae (33 of 160, 20.6%) were the most common typical causative pathogens isolated in both groups in the bacteriology intent-to-treat population. Clinical success in the clinical per protocol population at test of cure (days 16 to 37), the primary efficacy endpoint, was 90.3% (223 of 247) for amoxicillin-clavulanate 2,000/125 mg and 87.6% (198 of 226) for amoxicillin-clavulanate 875/125 mg (treatment difference, 2.7; 95% confidence interval, –3.0, 8.3). Bacteriological success at test of cure in the bacteriology per protocol population was 86.6% (58 of 67) for amoxicillin-clavulanate 2,000/125 mg and 78.4% (40 of 51) for amoxicillin-clavulanate 875/125 mg (treatment difference, 8.1%; 95% confidence interval, –5.8, 22.1). Both therapies were well tolerated. Amoxicillin-clavulanate 2,000/125 mg twice daily was shown to be as clinically effective as amoxicillin-clavulanate 875/125 mg twice daily for 7 days in the treatment of adult patients with community-acquired pneumonia, without a noted increase in the reported rate of adverse events.

Contributing members of the 600 Study Group are listed in Acknowledgments.

This article has been cited by other articles:

• Christ-Crain, M., Stolz, D., Bingisser, R., Muller, C., Miedinger, D., Huber, P. R., Zimmerli, W., Harbarth, S., Tamm, M., Muller, B. (2006). Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial. Am. J. Respir. Crit. Care Med. 174: 84-93 [Abstract] [Full Text]  
• Siquier, B., Sanchez-Alvarez, J., Garcia-Mendez, E., Sabria, M., Santos, J., Pallares, R., Twynholm, M., Dal-Re, R., on behalf of the 620 Clinical Study Group, (2006). Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 57: 536-545 [Abstract] [Full Text]  
• Yu, V. L., Klugman, K. P., Wagener, M. M., Chiou, C. C., Baddour, L. M. (2005). Is Combination the Only Issue?. Am. J. Respir. Crit. Care Med. 172: 1474-1474 [Full Text]